158 related articles for article (PubMed ID: 9095330)
1. Dose intensification of mitoxantrone in combination with levofolinic acid, fluorouracil, cyclophosphamide and granulocyte colony stimulating factor support in advanced untreated breast cancer patients. A multicentric phase II study of the Southern Italy Oncology Group.
Colucci G; Giotta F; Gebbia V; Riccardi F; Pezzella G; Durini E; Caruso M; Romito S; Gebbia N
Anticancer Drugs; 1997 Mar; 8(3):257-64. PubMed ID: 9095330
[TBL] [Abstract][Full Text] [Related]
2. Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM).
Colucci G; Romito S; Gebbia V; Pacilio G; Giotta F; Testa A; Pezzella G; Durini E; Agostara B; Cariello S
Br J Cancer; 1995 Nov; 72(5):1245-50. PubMed ID: 7577476
[TBL] [Abstract][Full Text] [Related]
3. A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients.
O'Shaughnessy JA; Denicoff AM; Venzon DJ; Danforth D; Pierce LJ; Frame JN; Bastian A; Ghosh B; Goldspiel B; Miller L
Ann Oncol; 1994 Oct; 5(8):709-16. PubMed ID: 7826903
[TBL] [Abstract][Full Text] [Related]
4. Mitoxantrone dose augmentation utilizing filgrastim support in combination with fixed-dose 5-fluorouracil and leucovorin in women with metastatic breast cancer.
Ingle JN; Kardinal CG; Suman VJ; Veeder MH; Schaefer PL; Kirschling RJ; Mailliard JA
Breast Cancer Res Treat; 1997 May; 43(3):193-200. PubMed ID: 9150898
[TBL] [Abstract][Full Text] [Related]
5. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
Gebbia V; Majello E; Testa A; Pezzella G; Giuseppe S; Giotta F; Riccardi F; Fortunato S; Colucci G; Gebbia N
Cancer; 1996 Sep; 78(6):1300-7. PubMed ID: 8826954
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II trial of human recombinant granulocyte-colony-stimulating factor (filgrastim) and escalating doses of cyclophosphamide, mitoxantrone, and 5-FU in the treatment of advanced breast cancer.
Budd GT; Atiba J; Silver RT; Palmer G; Armstrong S; Otto K; Presant C
J Cancer Res Clin Oncol; 1999; 125(8-9):500-4. PubMed ID: 10480343
[TBL] [Abstract][Full Text] [Related]
7. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
Shapiro CL; Ayash L; Webb IJ; Gelman R; Keating J; Williams L; Demetri G; Clark P; Elias A; Duggan D; Hayes D; Hurd D; Henderson IC
J Clin Oncol; 1997 Feb; 15(2):674-83. PubMed ID: 9053493
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of high-dose mitoxantrone plus cyclophosphamide and filgrastim in patients with advanced breast carcinoma.
Sparano JA; Robert N; Silverman P; Lazarus H; Malik U; Venkatraj U; Sarta C
J Clin Oncol; 1996 Sep; 14(9):2576-83. PubMed ID: 8823338
[TBL] [Abstract][Full Text] [Related]
10. An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer.
Bonnefoi H; Biganzoli L; Cufer T; Mauriac L; Hamilton A; Schaefer P; Piccart M
Breast Cancer Res Treat; 2001 Nov; 70(1):55-63. PubMed ID: 11768362
[TBL] [Abstract][Full Text] [Related]
11. High-dose mitoxantrone and cyclophosphamide without stem cell support in patients with high-risk and advanced breast carcinoma: a Phase II multicentric trial.
Pérez-Gracia JL; Colomer R; Esteban E; Barceló R; Benavides M; Puertas J; Arcediano A; Tornamira MV; Valentín V; Muñoz A; Cortés-Funes H; Hornedo J
Cancer; 2001 Nov; 92(10):2508-16. PubMed ID: 11745183
[TBL] [Abstract][Full Text] [Related]
12. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Edelman MJ; Meyers FJ; Houston J; Lauder I
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
[TBL] [Abstract][Full Text] [Related]
14. Randomized, controlled, multicenter phase III trial of standard-dose fluorouracil-epirubicin-cyclophosphamide (FEC), compared with time-intensive FEC (FEC-G) and mitoxantrone-methotrexate-mitomycin C (MMM-G) in metastatic breast carcinoma.
Capotorto AM; Pavesi L; Pedrazzoli P; Da Prada GA; Zamagni C; Massidda B; Farris A; Martoni A; Lelli G; Robustelli della Cuna G
J Chemother; 2003 Apr; 15(2):184-91. PubMed ID: 12797397
[TBL] [Abstract][Full Text] [Related]
15. A phase I-II study of cyclophosphamide, epidoxorubicin, levofolinic acid/5-fluorouracil and recombinant human granulocyte colony stimulating factor in metastatic breast carcinoma.
Callari A; Gebbia V; Testa A; Cusimano MP; Cipolla C; Amato C; Cannata G; Latteri MA; Garascia C; Gebbia N
Acta Oncol; 1994; 33(8):925-9. PubMed ID: 7529516
[TBL] [Abstract][Full Text] [Related]
16. Accelerated chemotherapy with high-dose epirubicin and cyclophosphamide plus r-met-HUG-CSF in locally advanced and metastatic breast cancer.
Scinto AF; Ferraresi V; Campioni N; Tonachella R; Piarulli L; Sacchi I; Giannarelli D; Cognetti F
Ann Oncol; 1995 Sep; 6(7):665-71. PubMed ID: 8664187
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of mitoxantrone plus cyclophosphamide and 5-fluorouracil in modulation with levo-folinate for advanced breast cancer patients.
Leonardi V; Meli M; Palmeri S; Russo A; Rini GB; Peralta S; Rausa L
J Chemother; 1995 Apr; 7(2):160-6. PubMed ID: 7545224
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer.
Venturini M; Del Mastro L; Testore F; Danova M; Garrone O; Lanfranco C; Latini F; Sertoli MR; Lionetto R; Queirolo P; Ardizzoni A; Rosso R
Cancer Chemother Pharmacol; 1996; 38(6):487-94. PubMed ID: 8823488
[TBL] [Abstract][Full Text] [Related]
19. Effective treatment of advanced breast cancer with vinorelbine, 5-fluorouracil and l-leucovorin plus human granulocyte colony-stimulating factor.
Kornek GV; Haider K; Kwasny W; Lang F; Krauss G; Hejna M; Raderer M; Weinländer G; Depisch D; Scheithauer W
Br J Cancer; 1998 Sep; 78(5):673-8. PubMed ID: 9744509
[TBL] [Abstract][Full Text] [Related]
20. Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer.
Kouroussis C; Androulakis N; Kakolyris S; Souglakos J; Kotsakis T; Mavroudis D; Katsogridakis K; Vardakis N; Hatzidaki D; Samonis G; Vlachonikolis J; Georgoulias V
J Clin Oncol; 1999 Mar; 17(3):862-9. PubMed ID: 10071277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
